Tuesday, July 10, 2018 8:17:32 PM
From the Australian exchange :
The Directors of MGC Pharmaceuticals Ltd (the “Company”) request that the Company’s securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company regarding the Good Manufacturing Practice (GMP) certification approval process being sought by the Company to commence production at its European Medicinal Cannabis Laboratory and Extraction Facility of pharmaceutical grade medicinal cannabis products.
The Company requests that the trading halt end on the earlier of the commencement of normal trading on Friday 13 July 2018, or when the announcement referred to above is released to the market.
The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM